Incyte's Q4 Loss Widens Despite Improved Jakafi Sales

Weaker contract revenue and higher expenses offset a 68% increase in sales of myelofibrosis drug Jakafi and push Incyte to a loss in the fourth-quarter.

Feb 12, 2014 at 1:37PM

Oncology and inflammation-focused biopharmaceutical company Incyte (NASDAQ:INCY) reported its fourth-quarter results before the opening bell today. Incyte's results point toward growing sales of its lead drug, but also growing losses.

For the quarter, Incyte reported total revenue -- which includes product revenue, royalty revenue, and contract revenue -- of $97.1 million, a 14.7% decline from this period last year. The company also reversed a year-ago profit of $18.8 million, or $0.14 per share, and reported a loss of $42.9 million, or $0.26 per share. Adjusting for a one-time charge related to the repurchase of $117.3 million in convertible senior notes executed during the quarter, Incyte lost $0.15 per share.

The big story for Incyte continues to be the growth of myelofibrosis drug Jakafi. Sales for the quarter grew 68% over the previous year to $72.9 million. Outside of the United States, where Jakafi is known under the brand name Jakavi and is licensed to partner Novartis (NYSE:NVS), Incyte recognized $8.4 million in royalty revenue, which is more than double the $3.7 million recognized during the fourth quarter last year.

Where Incyte's top line lost traction was with its contract revenue, which totaled just $15.8 million this quarter compared to $66.7 million in the year-ago period. This figure, which is merely an amortization of milestone payments received, included a $40 million milestone for Jakavi's European approval in 2012, and a $50 million payment from Eli Lilly with regard to bacritinib.

As you might suspect with the rollout of Jakafi, operating expenses were up across the board. Research and development costs climbed to $75 million from $59.8 million, and selling, general, and administrative expenses rose to $38 million from $23.7 million. Incyte attributed these higher costs to expanded pipeline activity and a growing marketing salesforce for Jakafi in the U.S.

Looking ahead, Incyte is forecasting full-year net product revenue for Jakafi of $315 million to $335 million, representing 38% year-over-year organic growth at the midpoint. Furthermore, Incyte is projecting $60 million in contract revenue in fiscal 2014. Losses appear likely to continue, however, with R&D expenses expected to range from $350 million to $370 million, and SG&A expenses rising to $145 million to $155 million in 2014, a jump of roughly $100 million and $40 million from fiscal 2013. 


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information